Pfizer, BioNTech amp up mRNA vaccine delivery targets amid Johnson & Johnson's delays

With Johnson & Johnson's COVID-19 vaccine rollout paused in the U.S. and delayed in Europe, mRNA partners Pfizer and BioNTech are stepping up to pledge accelerated delivery timelines and more doses.

Late Tuesday, Pfizer's CEO Albert Bourla said the company has "ramped up production" and can deliver another 20 million doses to the U.S. by the end of May. The company can supply its U.S. full order of 300 million doses two weeks earlier than planned, or around mid-July.